Charles Schwab Investment Management Inc. boosted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 14.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,028,924 shares of the company's stock after purchasing an additional 129,749 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.09% of Teva Pharmaceutical Industries worth $22,677,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently added to or reduced their stakes in the company. Diversify Advisory Services LLC raised its stake in Teva Pharmaceutical Industries by 2.5% in the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock valued at $426,000 after purchasing an additional 496 shares during the last quarter. Sanctuary Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 1.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock valued at $601,000 after buying an additional 664 shares during the period. Metis Global Partners LLC grew its holdings in Teva Pharmaceutical Industries by 6.7% in the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock valued at $302,000 after buying an additional 860 shares during the period. DGS Capital Management LLC grew its holdings in Teva Pharmaceutical Industries by 6.8% in the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company's stock valued at $246,000 after buying an additional 872 shares during the period. Finally, Williamson Legacy Group LLC grew its holdings in Teva Pharmaceutical Industries by 1.7% in the 4th quarter. Williamson Legacy Group LLC now owns 57,824 shares of the company's stock valued at $1,274,000 after buying an additional 979 shares during the period. Institutional investors and hedge funds own 54.05% of the company's stock.
Wall Street Analysts Forecast Growth
TEVA has been the subject of several recent analyst reports. Bank of America lowered their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Barclays lowered their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. Piper Sandler lifted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday. Finally, UBS Group decreased their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $23.43.
Read Our Latest Stock Report on TEVA
Teva Pharmaceutical Industries Trading Down 0.4 %
Shares of NYSE:TEVA traded down $0.07 during trading on Friday, reaching $16.18. 9,419,423 shares of the stock were exchanged, compared to its average volume of 9,441,915. The firm has a market cap of $18.34 billion, a price-to-earnings ratio of -11.16, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries Limited has a 12-month low of $12.51 and a 12-month high of $22.80. The firm's 50-day moving average price is $17.79 and its 200 day moving average price is $18.21. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.
Teva Pharmaceutical Industries Company Profile
(
Free Report)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Read More
Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
